# EDGAR Filing Document

**Accession Number:** 0001454789
**File Stem:** 0001140361-26-002207
**Filing Date:** 2026-1
**Character Count:** 8594
**Document Hash:** 6ddd7ce0832380487a796e2db94afd23
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-002207.hdr.sgml**: 20260123

**ACCESSION NUMBER**: 0001140361-26-002207

**CONFORMED SUBMISSION TYPE**: POS AM

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260123

**DATE AS OF CHANGE**: 20260123

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Astria Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001454789
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** POS AM
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-271848
- **FILM NUMBER:** 26556973

**BUSINESS ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 617-349-1971

**MAIL ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CATABASIS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20090127

#### As filed with the Securities and Exchange Commission on January 23, 2026

#### Registration No. 333-212382

#### Registration No. 333-231441

#### Registration No. 333-254174

#### Registration No. 333-264911

#### Registration No. 333-271848

#### Registration No. 333-276057

#### <br>

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-212382

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-231441

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-254174

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-264911

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-271848

#### Post-Effective Amendment No. 1 to Registration Statement No. 333-276057

#### to

### FORM S-3

#### REGISTRATION STATEMENT

#### UNDER

#### THE SECURITIES ACT OF 1933

## ASTRIA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **26-3687168** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) |

---

#### 22 Boston Wharf Road

#### 10<sup>th</sup> Floor

#### Boston, Massachusetts 02210
(Address, including zip code, and telephone number, including area

code, of registrant's principal executive offices)

#### Alane Barnes

#### Secretary

#### 4505 Emperor Blvd., Suite 200

#### Durham, North Carolina 27703
(919) 859-1302

(Name, address, including zip code, and telephone number,

including area code, of agent for service)

#### Approximate Date of Commencement of Proposed Sale to the Public: Not applicable.
If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

<br> If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

#### DEREGISTRATION OF SECURITIES
This Post-Effective Amendment (the "Post-Effective Amendment") relates to the following Registration Statements on Form S-3 (each, a "Registration Statement" and together, the "Registration Statements"):

• Registration Statement on Form S-3 (No. 333-212382), pertaining to the registration and sale from time to time of up to $100,000,000 of securities of Astria Therapeutics, Inc. (the "Company");

• Registration Statement on Form S-3 (No. 333-231441), pertaining to the registration and sale from time to time of up to $250,000,000 of securities of the Company;

• Registration Statement on Form S-3 (No. 333-254174), pertaining to the registration and sale from time to time of up to 92,399,805 shares of the Company's common stock, par value $0.001 per share by the selling stockholders identified in the prospectus;

• Registration Statement on Form S-3 (No. 333-264911), pertaining to the registration and sale from time to time of up to $250,000,000 of securities of the Company;

• Registration Statement on Form S-3 (No. 333-271848), pertaining to the registration and sale from time to time of up to $250,000,000 of securities of the Company; and

• Registration Statement on Form S-3 (No. 333-276057), pertaining to the registration and sale from time to time of up to $559,134,123 of securities of the Company.

On January 23, 2026, pursuant to the Agreement and Plan of Merger, dated as of October 14, 2025, by and between BioCryst Pharmaceuticals, Inc., a Delaware corporation ("BioCryst"), Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst ("Merger Sub"), and the Company, Merger Sub was merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of BioCryst.

As a result of the Merger, the offering and sale of securities under the above-listed Registration Statements under the Securities Act of 1933, as amended, which have been previously filed with the Securities and Exchange Commission, have been terminated. In accordance with the undertakings made by the Company in the Registration Statements to remove from registration by means of a post-effective amendment any of the securities that remain unsold at the termination of the offering, the Company hereby terminates the effectiveness of the Registration Statements and removes from registration the securities of the Company registered but unsold under the Registration Statements as of the date hereof. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.

------

#### SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina on January 23, 2026.

---

| | |
|:---|:---|
| **ASTRIA THERAPEUTICS, INC.** | **ASTRIA THERAPEUTICS, INC.** |
| By: | /s/ Alane Barnes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  |
|  | Alane Barnes |
|  | Secretary |

---

No other person is required to sign this Post-Effective Amendment to each Registration Statement in reliance upon Rule 478 under the Securities Act of 1933, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;<br>

------